Scientists at Heriot-Watt University are working towards creating the world's first artificial human livers for drug testing to drastically cut the number of live animals used and get life-saving medicines into the clinic ...
Nov 13, 2012
0
0
A new prototype for medicated chewing gum has been developed for motion sickness that may offer many advantages over conventional oral solid dosage forms. About 33 percent of people are susceptible to motion sickness in mild ...
Oct 17, 2012
0
0
Drawing on recent findings of a significant rise in cases of drug-resistant tuberculosis in the UK and globally, top TB researchers at a briefing today in London called for greater focus on the quest for new vaccines—a ...
Oct 15, 2012
0
0
Washington State University researchers have developed a new drug candidate that dramatically improves the cognitive function of rats with Alzheimer's-like mental impairment.
Oct 11, 2012
7
0
CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.
Sep 26, 2012
0
0
A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown ...
Sep 17, 2012
0
0
(Medical Xpress)—A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for ...
Sep 17, 2012
0
0
(Medical Xpress)—University of Rochester Medical Center scientists believe they are the first to identify genes that underlie the growth of primitive leukemia stem cell, and then to use the new genetic signature to identify ...
Aug 27, 2012
0
0
The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc. (TSX: MDG; OTCQX: ...
Aug 16, 2012
0
0
Researchers from Munich and Naples have shown that minimal modification of a synthetic peptide with anti-HIV activity results in a new compound with more than two orders of magnitude higher binding affinity to the chemokine ...
Aug 9, 2012
0
0
